What is Day Zero Diagnostics?
Day Zero Diagnostics, Inc., based in Boston, is at the forefront of infectious disease diagnostics, leveraging whole-genome sequencing and machine learning. The company's innovative approach aims to rapidly identify pathogens and their antibiotic resistance profiles, bypassing traditional culture methods. This technology is crucial for combating the escalating threat of antibiotic resistance and enabling large-scale management of healthcare-associated infections. Founded by a team of experts from Harvard University and Massachusetts General Hospital, Day Zero Diagnostics has garnered recognition from leading health and innovation organizations.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised a total of $55.3M across 6 funding rounds:
Angel/Seed
$3M
Series A
$8.6M
Corporate Investment
$6.2M
Debt
$467K
Unspecified
$21M
Other Financing Round
$16M
Angel/Seed (2017): $3M with participation from Sands Capital and Golden Seeds
Series A (2019): $8.6M, investors not publicly disclosed
Corporate Investment (2020): $6.2M supported by Carb-X
Debt (2021): $467K featuring PPP
Unspecified (2022): $21M backed by Triventures, Sands Capital, Golden Seeds, Panacea Ventures, Hongkou Capital, and BD
Other Financing Round (2023): $16M, investors not publicly disclosed
Key Investors in Day Zero Diagnostics
Carb-X
CARB-X is a global accelerator focused on supporting the development of new antibiotics and diagnostics to combat drug-resistant bacteria, investing in early-stage projects to ensure effective treatments are available worldwide.
Triventures
Triventures is a global venture capital fund investing in early-stage companies with breakthroughs in healthcare and data-driven technologies, aiming to foster transformative solutions through a strong network.
Sands Capital
Sands Capital Management is an investment firm headquartered in Arlington, Virginia, managing equity mutual funds and investing in public equity markets since its establishment in 1992.
What's next for Day Zero Diagnostics?
The recent enterprise-level funding positions Day Zero Diagnostics for significant scaling and further development of its diagnostic platform. This strategic investment is expected to accelerate the company's mission to revolutionize infectious disease treatment and management. Future growth will likely focus on expanding market reach, enhancing technological capabilities, and forging strategic partnerships to combat global health challenges related to antimicrobial resistance.
See full Day Zero Diagnostics company page
